Status:

UNKNOWN

Sentinel Node in Endometrial Cancer

Lead Sponsor:

Judit Pich Martínez

Conditions:

Endometrial Cancer

Eligibility:

FEMALE

18+ years

Phase:

PHASE2

Brief Summary

Phase II, open-label, randomized pilot study. Patients will be randomized (1:1) to receive for sentinel node screening: 1. Radiotracer (RT) via cervical administration and TUMIR 2. Combination of RT...

Eligibility Criteria

Inclusion

  • Age ≥ 18 years.
  • Histological diagnosis of endometrial cancer with criteria of high risk according to the following criteria: - unfavorable histology according to FIGO (adenocarcinoma serous, clear cell, or carcinosarcoma) - nuclear grade 3 - suspected myometrial invasion\> 50% by resonance magnetic (MR) or transvaginal ultrasound
  • Women of childbearing age should have a transvaginal ultrasound who rule out pregnancy and must commit to using methods highly effective contraceptives (vasectomized couple and sexual abstinence) until the hysterectomy is performed.
  • Patient who gives written informed consent.

Exclusion

  • Pregnancy or lactation.
  • Suspected lymph node or distant metastatic disease in the preoperative study.
  • History of previous surgery or radiotherapy in the pelvic and paraortic lymphatic drainage areas or nodal involvement of any other etiology.
  • Body mass index (BMI) greater than 45 Kg / m2.
  • Patients who, in the researcher's opinion, are not suitable for participate, regardless of reason, including medical or clinical, or participants potentially at risk of not comply with the study procedures.
  • Known hypersensitivity to some of the active substances or excipients from RT or ICG (including previous history of hypersensitivity to products containing human albumin).
  • Hypersensitivity to sodium iodide.
  • Patients allergic to iodine.
  • Patients with clinical hyperthyroidism, thyroid adenomas autonomic and diffuse focal and autonomic disturbances of the gland thyroid.

Key Trial Info

Start Date :

October 5 2020

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

September 30 2023

Estimated Enrollment :

70 Patients enrolled

Trial Details

Trial ID

NCT04492995

Start Date

October 5 2020

End Date

September 30 2023

Last Update

September 18 2023

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Hospital Clínic de Barcelona

Barcelona, Spain, 08036